Dates: July 12-15, 2026
Location: ExCeL London, United Kingdom
Organizer: [Alzheimer's Association](https://www.alz.org/)
Session Times: 11:00 AM - 12:15 PM BST (daily)
Overview
flowchart TD
events_aaic_2026_plenary_sessi["AAIC 2026 Plenary Sessions"]
style events_aaic_2026_plenary_sessi fill:#4fc3f7,stroke:#333,color:#000
events_aaic_2026_ple_0["Conference Context"]
events_aaic_2026_plenary_sessi -->|"includes"| events_aaic_2026_ple_0
style events_aaic_2026_ple_0 fill:#81c784,stroke:#333,color:#000
events_aaic_2026_ple_1["Role of Plenary Sessions at AAIC"]
events_aaic_2026_plenary_sessi -->|"includes"| events_aaic_2026_ple_1
style events_aaic_2026_ple_1 fill:#ef5350,stroke:#333,color:#000
events_aaic_2026_ple_2["AAIC 2026 Scientific Themes"]
events_aaic_2026_plenary_sessi -->|"includes"| events_aaic_2026_ple_2
style events_aaic_2026_ple_2 fill:#ffd54f,stroke:#333,color:#000
events_aaic_2026_ple_3["Plenary Session Schedule"]
events_aaic_2026_plenary_sessi -->|"includes"| events_aaic_2026_ple_3
style events_aaic_2026_ple_3 fill:#ce93d8,stroke:#333,color:#000
events_aaic_2026_ple_4["Sunday, July 12, 2026 Opening Plenary"]
events_aaic_2026_plenary_sessi -->|"includes"| events_aaic_2026_ple_4
style events_aaic_2026_ple_4 fill:#4fc3f7,stroke:#333,color:#000
events_aaic_2026_ple_5["Monday, July 13, 2026 Featured Plenary"]
events_aaic_2026_plenary_sessi -->|"includes"| events_aaic_2026_ple_5
style events_aaic_2026_ple_5 fill:#81c784,stroke:#333,color:#000
...Dates: July 12-15, 2026
Location: ExCeL London, United Kingdom
Organizer: [Alzheimer's Association](https://www.alz.org/)
Session Times: 11:00 AM - 12:15 PM BST (daily)
Overview
Mermaid diagram (expand to render)
The plenary sessions at AAIC 2026 represent the centerpiece of the conference, featuring invited presentations from world-leading researchers on the most significant advances in Alzheimer's disease, dementia, and related neurodegenerative conditions. These sessions provide attendees with comprehensive updates on the state of Alzheimer's research, therapeutic development, and emerging scientific insights that will shape the field's future direction["@aaic2026"].
The plenary program at AAIC 2026 reflects the remarkable transformation in Alzheimer's research over the past decade—from a field with limited therapeutic options to one with multiple disease-modifying therapies approved and numerous programs in clinical development. The sessions synthesize cutting-edge basic science discoveries with clinical translation insights, providing a comprehensive view of where the field stands and where it is heading.
Conference Context
Role of Plenary Sessions at AAIC
Plenary sessions serve multiple critical functions at the Alzheimer's Association International Conference:
Synthesis of Major Advances: Presenters distill complex research into accessible summaries of the most important findings
Cross-Disciplinary Integration: Sessions bring together basic scientists, clinicians, and clinical trialists
Future Directions: Plenary speakers often present unpublished data and discuss emerging hypotheses
Career Development: Junior researchers observe senior investigators presenting landmark findings
Media Attention: Plenary presentations frequently generate media coverage and influence public understandingAAIC 2026 Scientific Themes
AAIC 2026 plenary sessions focus on several major scientific themes:
- Amyloid and Tau Biology: Understanding the relationship between core pathological proteins
- Neuroimmune Interactions: Microglial biology and neuroinflammation
- Biomarker Evolution: Blood-based biomarkers and their clinical application
- Therapeutic Translation: From mechanism to approved therapy
- Prevention Strategies: Primary and secondary prevention approaches
Plenary Session Schedule
Sunday, July 12, 2026 — Opening Plenary
Theme: "The State of Alzheimer's Science: Translating Progress into Promise"
The opening plenary session sets the stage for AAIC 2026 by providing an overview of the current state of Alzheimer's research and therapy development. Expected topics include:
- Overview of Approved Therapies: Summary of lecanemab and donanemab clinical data
- Pipeline Landscape: Review of therapies in clinical development
- Biomarker Integration: How biomarkers are transforming clinical trial design
- Global Perspectives: Alzheimer's research worldwide
The opening session typically features the Alzheimer's Association Chief Science Officer and prominent clinical researchers.
Monday, July 13, 2026 — Featured Plenary
Theme: "Neuroinflammation and Immune Responses in Alzheimer's Disease"
The Monday plenary focuses on the critical role of neuroinflammation in Alzheimer's disease pathogenesis[@heneka2015]. Expected content includes:
- Microglial Biology: Latest understanding of microglial activation states
- TREM2 Biology: TREM2 variants and microglial function
- Complement System: Role of complement in synaptic pruning
- Therapeutic Implications: Anti-inflammatory and immunomodulatory approaches
Tuesday, July 14, 2026 — Keynote Address
Theme: "From Amyloid to Z: Integrating Multiple Mechanisms in Alzheimer's Disease"
The keynote address provides an integrative view of Alzheimer's disease pathogenesis[@scheltens2016]. Topics expected include:
- Amyloid Cascade Hypothesis: Current status and modifications
- Tau Propagation: Mechanisms of tau spreading
- Vascular Contributions: Vascular factors in neurodegeneration
- Metabolic Dysfunction: Role of metabolic disease in dementia
- Systems Integration: How multiple mechanisms interact
Wednesday, July 15, 2026 — Closing Plenary
Theme: "The Future of Alzheimer's Prevention and Treatment"
The closing plenary looks forward to the future of the field:
- Prevention Trials: Updates on primary prevention studies
- Combination Therapies: Approaches targeting multiple mechanisms
- Precision Medicine: Biomarker-driven patient selection
- Global Initiatives: World Health Organization and national dementia plans
Major Scientific Topics
Amyloid and Tau Biology
The relationship between amyloid-beta and tau pathology remains central to Alzheimer's disease research[@battaglia2022]. Plenary presentations are expected to address:
Amyloid Pathology
- Oligomer Hypotheses: Evidence for soluble oligomers as the toxic species
- Amyloid-Related Imaging Abnormalities (ARIA): Mechanisms and management
- Amyloid Clearance: How anti-amyloid therapies work
- Amyloid Independence: Evidence for amyloid-independent pathways
Tau Pathology
- Tau Spreading: Prion-like propagation mechanisms
- Post-Translational Modifications: Phosphorylation, acetylation, truncation
- Tau PET: Imaging tau pathology in living patients
- Tau-Targeting Therapies: Anti-tau antibodies and small molecules
The NIA-AA Research Framework emphasizes amyloid, tau, and neurodegeneration (AT(N) biomarker categories[@jack2018], and plenary sessions regularly address each component.
Neuroinflammation
Neuroinflammation has emerged as a critical component of Alzheimer's disease pathogenesis[@heneka2015]:
Microglial Biology
- Disease-Associated Microglia (DAM): Microglial activation states
- TREM2 Variants: Genetic links between microglial function and AD risk
- Microglial Dysfunction: How microglial failure contributes to disease
- CSF1R Inhibition: Microglial depletion approaches
Neuroimmune Interactions
- Complement System: C1q and C3 in synapse elimination
- NLRP3 Inflammasome: Inflammatory signaling in neurodegeneration
- Astrocyte Reactivity: A1/A2 astrocyte phenotypes
- Blood-Brain Barrier: Immune cell trafficking in AD
Biomarkers
Biomarkers have transformed Alzheimer's clinical trials and are expected to feature prominently in plenary sessions:
Fluid Biomarkers
- Tau Biomarkers: p-tau217, p-ttau181 in blood
- Amyloid Biomarkers: Aβ42/40 ratio in CSF and blood
- Neurodegeneration: Neurofilament light chain (NFL)
- Astrocytic Markers: GFAP as marker of astrogliosis
Imaging Biomarkers
- Amyloid PET: Standardized quantification (Centiloid)
- Tau PET: Regional tau and clinical correlation
- FDG PET: Metabolic dysfunction patterns
- Structural MRI: atrophy measures
The development of blood-based biomarkers is revolutionizing Alzheimer's diagnosis and clinical trial design, enabling earlier detection and more efficient screening.
Therapeutic Translation
With multiple disease-modifying therapies now approved, therapeutic translation is a major plenary focus[@long2023]:
Approved Therapies
- Lecanemab: Mechanism, clinical trial results, real-world experience
- Donanemab: TRAILBLAZER program data, approved indications
Pipeline Programs
- Anti-Amyloid Programs: New antibodies in development
- Anti-Tau Approaches: Immunotherapies and small molecules
- Neuroprotective Strategies: Synaptic preservation, metabolic support
- Combination Approaches: Multi-target strategies
Prevention Strategies
Primary and secondary prevention trials represent the cutting edge of Alzheimer's intervention:
Primary Prevention
- DIAN-TU: Prevention in autosomal dominant AD
- A4 Study: Anti-amyloid in preclinical AD
- Other Prevention Trials: Various approaches in cognitively normal individuals
Secondary Prevention
- Leqembi Prevention: Studies in preclinical populations
- Lifestyle Interventions: Diet, exercise, cognitive engagement
Plenary Speaker Profiles
Expected Speakers
AAIC 2026 plenary sessions feature internationally recognized leaders in Alzheimer's research:
- Academic Leaders: Leading researchers from major universities
- Industry Scientists: Chief Scientific Officers from pharmaceutical companies
- Clinical Experts: Clinicians with extensive trial experience
- Government Representatives: NIH and FDA officials
Speaker Selection
Plenary speakers are selected by the AAIC Scientific Program Committee based on:
- Scientific Impact: Discovery of major importance
- Field Representation: Balanced representation across research areas
- Diversity: Geographic, gender, and career stage diversity
- Presentation Quality: Track record of impactful presentations
Presentation Structure
Each plenary session follows a structured format:
Introduction (5 minutes): Session chair introduces the topic and speaker
Main Presentation (35-40 minutes): In-depth coverage of the topic
Question and Answer (15-20 minutes): Audience questionsAudience Interaction
- Live Q&A: Questions from attendees in person
- Online Questions: Questions submitted via conference app
- Session Hashtag: Social media engagement using #AAIC2026
Satellite Symposia
Plenary sessions are complemented by industry-sponsored satellite symposia providing additional in-depth coverage of specific topics.
Scientific Sessions
Concurrent scientific sessions allow for more detailed presentations on specialized topics:
- Poster Sessions: Interactive presentations from researchers
- Oral Abstracts: Selected abstract presentations
- Focused Workshops: Hands-on learning opportunities
Networking Opportunities
- Poster Sessions: Network with presenting researchers
- Social Events: Conference receptions and dinners
- Exhibition Floor: Engage with companies and organizations
Impact on the Field
Research Direction
Plenary presentations at AAIC frequently influence research directions:
- New Hypotheses: Presentations generate new research questions
- Methodological Advances: New approaches are shared and adopted
- Collaborative Opportunities: Connections formed during sessions lead to collaborations
Clinical Practice
- Trial Results: Clinical trial data influences practice guidelines
- Diagnostic Advances: New diagnostic approaches enter practice
- Therapeutic Updates: Approved therapy guidance
Public Health
- Media Coverage: Major findings receive media attention
- Policy Influence: Research informs public health policy
- Awareness: Conference raises Alzheimer's awareness
Related NeuroWiki Content
Alzheimer's Disease
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Alzheimer's Disease Pathophysiology](/mechanisms/alzheimers-pathophysiology)
- [Amyloid Cascade Hypothesis](/mechanisms/amyloid-cascade)
Key Proteins and Pathways
- [Amyloid-beta Protein](/proteins/amyloid-beta)
- [Tau Protein](/proteins/tau)
- [TREM2 Protein](/proteins/trem2)
- [Neuroinflammation Pathway](/mechanisms/neuroinflammation)
Therapeutic Approaches
- [Anti-Amyloid Therapies](/therapeutics/anti-amyloid-therapies)
- [Leqembi](/therapeutics/leqembi)
- [Donanemab](/therapeutics/donanemab)
- [AAIC 2026 Conference](/events/aaic-2026)
- [AAIC 2026 Company Presentations](/events/aaic-2026-company-presentations)
- [AAIC 2026 Scientific Sessions](/events/aaic-2026-scientific-sessions)
- [AAIC 2026 Clinical Trials](/events/aaic-2026-clinical-trials)
- [Conference Index](/events/conference-index)
External Resources
- [AAIC 2026 Official Program](https://aaic.alz.org/program)[@aaic2026]
- [AAIC Archive](https://aaic.alz.org/archives)[@aaic_archive]
- [Alzheimer's Association](https://www.alz.org/)
- [PubMed Search: Alzheimer's Disease](https://pubmed.ncbi.nlm.nih.gov/?term=Alzheimer+disease)
Key References
[AAIC 2026 Official Program (2026)](https://aaic.alz.org/program)
[AAIC Plenary Sessions Archive](https://aaic.alz.org/archives)
[Battaglia et al., Amyloid and tau interactions in Alzheimer's disease (2022)](https://pubmed.ncbi.nlm.nih.gov/35642084/)
[Heneka et al., Neuroinflammation in Alzheimer's disease (2015)](https://pubmed.ncbi.nlm.nih.gov/25998905/)
[Scheltens et al., Alzheimer's disease (2016)](https://pubmed.ncbi.nlm.nih.gov/27064282/)
[Jack et al., NIA-AA Research Framework (2018)](https://pubmed.ncbi.nlm.nih.gov/29653606/)
[Selkoe & Hardy, The amyloid hypothesis at 25 years (2019)](https://pubmed.ncbi.nlm.nih.gov/31074661/)
[Long & Holtzman, Alzheimer disease (2023)](https://pubmed.ncbi.nlm.nih.gov/37047030/)